Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9961949 | 0.92 | KIF11 (0.63) | KIF11TP53MAPTABCG2LMNA | |
| SCHEMBL9961950 | 0.92 | KIF11 (0.63) | KIF11TP53MAPTABCG2LMNA | |
| SCHEMBL764649 | 0.91 | KIF11 (0.58) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL4924334 | 0.88 | LMNA (0.56) | KIF11TP53MAPTABCG2LMNA | |
| SCHEMBL765163 | 0.88 | TP53 (0.55) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL764923 | 0.87 | TP53 (0.66) | KIF11TP53MAPTSMN1; SMN2ABCG2 | |
| SCHEMBL9961948 | 0.86 | KIF11 (0.72) | KIF11TP53MAPTABCG2LMNA | |
| SCHEMBL8402610 | 0.86 | KIF11 (0.72) | KIF11TP53MAPTABCG2LMNA | |
| SCHEMBL4923677 | 0.85 | LMNA (0.58) | KIF11TP53MAPTABCG2LMNA | |
| SCHEMBL765185 | 0.85 | TP53 (0.63) | KIF11TP53MAPTSMN1; SMN2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION | 2008-05-01 | — | — | US | claimed |
| EP-1786425-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SmithKline Beecham Corporation (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2007002051-A1 | CARBOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF FLAVIVIRIDAE INFECTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-04 | — | — | WO | claimed |
| WO-2006015035-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-09 | — | — | WO | claimed |
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | US | disclosed |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | PTC THERAPEUTICS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| EP-2434891-B9 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | PTC THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3718405-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC Therapeutics, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-2434891-B1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | PTC THERAPEUTICS, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | PTC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION | 2008-05-01 | — | — | US | disclosed |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION | 2008-05-01 | — | — | US | disclosed |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION | 2008-05-01 | — | — | US | disclosed |
| EP-1786425-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SmithKline Beecham Corporation (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2007002051-A1 | CARBOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF FLAVIVIRIDAE INFECTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002051-A1 | CARBOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF FLAVIVIRIDAE INFECTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006015035-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043422-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KIF11 2547/4885TP53 15/4885MAPT 3300/4885 |
| US-20160340354-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KIF11 2569/4885TP53 16/4885MAPT 3328/4885 |
| US-20190194188-A1 | METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS | HDGF, POLRMT, VEGFA | KIF11 2569/4885TP53 16/4885MAPT 3328/4885 |
| US-20200317668-A1 | METHOD OF INHIBITING OR REDUCING A CORONAVIRIDAE VIRUS INFECTION | SARS1, POLRMT, EIF2AK2 | KIF11 3683/4885TP53 1818/4885MAPT 2964/4885 |
| US-11613538-B2 | Method of inhibiting or reducing a viral infection | SARS1, EIF2AK2, POLRMT | KIF11 3731/4885TP53 1710/4885MAPT 2901/4885 |
| US-20080103164-A1 | USEFUL COMPOUNDS FOR HPV INFECTION | TP53, POLI, PCNA | KIF11 3280/4885TP53 1/4885MAPT 4453/4885 |
| US-20120157400-A1 | METHODS FOR TREATING KAPOSI SARCOMA | HDGF, HIF1AN, VEGFA | KIF11 1065/4885TP53 17/4885MAPT 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.